Download PDF
Z Geburtshilfe Neonatol 2017; 221(06): 272-275
DOI: 10.1055/s-0043-116017
Review
© Georg Thieme Verlag KG Stuttgart · New York

Palliative Therapies for Congenital Heart Disease with Ductus Dependent Pulmonary Circulation

Shi-Min Yuan
1   Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, China
› Author Affiliations
Further Information

Publication History

received 28 March 2017

accepted 28 June 2017

Publication Date:
15 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

In neonates, the management of ductus dependent pulmonary circulation is challenging. There have been three palliative therapies for this lesion: the modified Blalock-Taussig shunt, ductal stenting and prostaglandin E infusions, for maintaining the ductal patency before definite operations. Debates remain with regard to the indications and disadvantages of three palliative therapies. The aim of this article is to give a brief review of these three palliative therapies.

Key words

congenital heart defects - ductus arteriosus - pulmonary circulation.
 

  • References

  • 1 Gournay V. The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis 2011; 104: 578-585
    CrossrefPubMedGoogle Scholar
  • 2 Habshan FA. Ductal-dependent forms of congenital heart disease: clinical significance of prenatal diagnosis. http://www.sha-conferences.com/files/presentation2011/005004.pdf, Accessed on March 25, 2017
    PubMed
  • 3 Viñals F, Tapia J, Giuliano A. Prenatal detection of ductal-dependent congenital heart disease: how can things be made easier?. Ultrasound Obstet Gynecol 2002; 19: 246-249
    CrossrefPubMedGoogle Scholar
  • 4 Kouatli A. Ductus arteriosus dependent congenital heart disease. www.sha-education.com/sites/all/sha23_presentations/27-1-2012/007002.pdf Accessed on March 25, 2017
    PubMed
  • 5 Hussain A, Al-Zharani S, Muhammed AA. et al. Midterm outcome of stent dilatation of patent ductus arteriosus in ductal-dependent pulmonary circulation. Congenit Heart Dis 2008; 3: 241-249
    CrossrefPubMedGoogle Scholar
  • 6 Yuan SM, Shinfeld A, Raanani E. The Blalock-Taussig shunt. J Card Surg 2009; 24: 101-108
    CrossrefPubMedGoogle Scholar
  • 7 Metras D, Kreitmann B, Riberi A. et al. A simple approach to takedown of a modified Blalock shunt. Ann Thorac Surg 1992; 53: 912-913
    CrossrefPubMedGoogle Scholar
  • 8 Küçük M, Özdemir R, Karaçelik M. et al. Risk factors for thrombosis, overshunting and death in infants after modified Blalock-Taussig shunt. Acta Cardiol Sin 2016; 32: 337-342
    PubMedGoogle Scholar
  • 9 McMullan DM, Permut LC, Jones TK. et al. Modified Blalock-Taussig shunt versus ductal stenting for palliation of cardiac lesions with inadequate pulmonary blood flow. J Thorac Cardiovasc Surg 2014; 147: 397-401
    CrossrefPubMedGoogle Scholar
  • 10 Yun SW. Congenital heart disease in the newborn requiring early intervention. Korean J Pediatr 2011; 54: 183-191
    CrossrefPubMedGoogle Scholar
  • 11 Akaike T, Minamisawa S. Prostaglandin E-mediated vascular remodeling of the ductus arteriosus and ductus-dependent congenital heart diseases. J Mol Genet Med 2016; 10: e109 10.4172/1747-0862.1000e109
    PubMedGoogle Scholar
  • 12 Gruzdev A, Nguyen M, Kovarova M. et al. PGE2 through the EP4 receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth. Prostaglandins Other Lipid Mediat 2012; 97: 109-119
    CrossrefPubMedGoogle Scholar
  • 13 Aydın B, Dilli D, Zenciroğlu A. et al. Intussusception in a term newborn with duct-dependent congenital heart disease. Dicle Tıp Dergisi 2013; 40: 105-108
    PubMedGoogle Scholar
  • 14 Huang FK, Lin CC, Huang TC. et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol 2013; 54: 102-106
    CrossrefPubMedGoogle Scholar
  • 15 Ustün N, Dilli D, Zenciroğlu A. et al. Long-term prostaglandin E1 use in newborns with duct-dependent congenital heart diseases: one year experience of a tertiary neonatal intensive care unit in Turkey. Anadolu Kardiyol Derg 2013; 13: 732-734
    PubMedGoogle Scholar
  • 16 Silove ED, Roberts DG, de Giovanni JV. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease. Arch Dis Child 1985; 60: 1025-1030
    CrossrefPubMedGoogle Scholar
  • 17 Kobayashi N, Aida N, Nishimura G. et al. Acute gastric outlet obstruction following the administration of prostaglandin: an additional case. Pediatr Radiol 1997; 27: 57-59
    CrossrefPubMedGoogle Scholar
  • 18 Sivakumar K, Bhagyavathy A, Coelho R. et al. Longevity of neonatal ductal stenting for congenital heart diseases with duct-dependent pulmonary circulation. Congenit Heart Dis 2012; 7: 526-533
    CrossrefPubMedGoogle Scholar
  • 19 Santoro G, Gaio G, Capozzi G. et al. Fate of hypoplastic pulmonary arteries after arterial duct stenting in congenital heart disease with duct-dependent pulmonary circulation. JACC Cardiovasc Interv 2015; 8: 1626-1632
    CrossrefPubMedGoogle Scholar
  • 20 Buys DG, Brown SC, Greig C. Stenting the arterial duct: practical aspects and review of outcomes. SAHeart 2013; 10: 514-519
    PubMedGoogle Scholar
  • 21 Alwi M, Choo KK, Latiff HA. et al. Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation. J Am Coll Cardiol 2004; 44: 438-445
    CrossrefPubMedGoogle Scholar